Voyager Therapeutics – IPO

Boston – November 19, 2015 – Cooley advised the underwriters on Voyager Therapeutics' $80.5 million initial public offering. Voyager is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system. The company now trades on the NASDAQ Global Select Market under the symbol "VYGR."

Cowen and Company and Piper Jaffray & Co. acted as joint book-running managers for the offering. Wedbush PacGrow and Nomura acted as co-managers.

The Cooley corporate and securities team advising the underwriters included Marc Recht, Richard Segal, Pia Kaur and Wilber Barillas.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.